PIC-1/SUMO-1-Modified PML-Retinoic Acid Receptor α Mediates Arsenic Trioxide-Induced Apoptosis in Acute Promyelocytic Leukemia

REFERENCES

• Alcalay, M., L. Tomassoni, E. Colombo, S. Stoldt, F. Grignani, M. Fagioli, L. Szekely, K. Helin, and J. Pelicci 1998. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol. Cell. Biol. 18:1084–1093.
   PubMedGoogle Scholar
• Ascoli, C. A., and J. Maul 1991. Identification of a novel nuclear domain. J. Cell Biol. 112:785–795.
   PubMed Web of Science ®Google Scholar
• Bloch, D. B., S. M. de la Monte, P. Guigaouri, A. Filippov, and J. Bloch 1996. Identification and characterization of a leukocyte-specific component of the nuclear body. J. Biol. Chem. 271:29198–29204.
   PubMedGoogle Scholar
• Boddy, M. N., K. Howe, L. D. Etkin, E. Solomon, and J. Freemont 1996. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukemia. Oncogene 13:971–982.
   PubMed Web of Science ®Google Scholar
• Chen, G. Q., X. G. Shi, W. Tang, S. M. Xiong, J. Zhu, X. Cai, Z. G. Han, J. H. Ni, G. Y. Shi, P. M. Jia, M. M. Liu, K. L. He, C. Niu, J. Ma, P. Zhang, T. D. Zhang, P. Paul, T. Naoe, K. Kitamura, W. Miller, S. Waxman, Z. Y. Wang, H. de The, S. J. Chen, and J. Chen 1997. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89:3345–3353.
   PubMed Web of Science ®Google Scholar
• Chen, G. Q., J. Zhu, X. G. Shi, J. H. Ni, H. J. Zhong, G. Y. Si, X. L. Jin, W. Tang, X. S. Li, S. M. Xong, Z. X. Shen, G. L. Sun, J. Ma, P. Zhang, T. D. Zhang, C. Gazin, T. Naoe, S. J. Chen, Z. Y. Wang, and J. Chen 1996. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88:1052–1061.
   PubMed Web of Science ®Google Scholar
• Chen, Z., N. J. Brand, A. Chen, S. J. Chen, J. H. Tong, Z. Y. Wang, S. Waxman, and J. Zelent 1993. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 12:1161–1167.
   PubMed Web of Science ®Google Scholar
• Collins, S. J. 1987. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 70:1233–1244.
   PubMed Web of Science ®Google Scholar
• Daniel, M. T., M. Koken, O. Romagne, S. Barbey, A. Bazarbachi, M. Stadler, M. C. Guillemin, L. Degos, C. Chomienne, and J. de The 1993. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82:1858–1867.
   PubMed Web of Science ®Google Scholar
• Degos, L. 1992. Retinoic acid in acute promyelocytic leukemia: a model for differentiation therapy. Curr. Opin. Oncol. 4:45–52.
   PubMedGoogle Scholar
• Degos, L., H. Dombret, C. Chomienne, M. T. Daniel, J. M. Miclea, C. Chastang, S. Castaigne, and J. Fenaux 1995. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85:2643–2653.
   PubMed Web of Science ®Google Scholar
• Dent, A. L., J. Yewdell, F. Puvion-Dutilleul, M. H. Koken, H. de The, and J. Staudt 1996. LYSP100-associated nuclear domain (LANDs): description of a new class of subnuclear structures and their relationship to PML nuclear bodies. Blood 88:1423–1426.
   PubMedGoogle Scholar
• Desbois, C., R. Rousset, F. Bantignies, and J. Jalinot 1996. Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I Tax oncoprotein. Science 273:951–953.
   PubMed Web of Science ®Google Scholar
• Dyck, J. A., G. G. Maul, W. H. Miller Jr., J. D. Chen, A. Kakizuka, and J. Evans 1994. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76:333–343.
   PubMed Web of Science ®Google Scholar
• Flenghi, L., M. Fagioli, L. Tomassoni, S. Pileri, M. Gambacorta, R. Pacini, F. Grignani, T. Casini, P. F. Ferrucci, M. F. Martelli et al.. 1995. Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. Blood 85:1871–1880.
   PubMed Web of Science ®Google Scholar
• Gianni, M., M. H. Koken, M. K. Chelbi-Alix, G. Benoit, M. Lanotte, Z. Chen, and J. de The 1998. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 91:4300–4310.
   PubMed Web of Science ®Google Scholar
• Gongora, C., G. David, L. Pintard, C. Tissot, T. D. Hua, A. Dejean, and J. Mechti 1997. Molecular cloning of a new interferon-induced PML nuclear body-associated protein. J. Biol. Chem. 272:19457–19463.
   PubMed Web of Science ®Google Scholar
• Grignani, F., M. Fagioli, M. Alcalay, L. Longo, P. P. Pandolfi, E. Donti, A. Biondi, F. Lo Coco, F. Grignani, and J. Pelicci 1994. Acute promyelocytic leukemia: from genetics to treatment. Blood 83:10–25.
   PubMed Web of Science ®Google Scholar
• Grignani, F., P. F. Ferrucci, U. Testa, G. Talamo, M. Fagioli, M. Alcalay, A. Mencarelli, F. Grignani, C. Peschle, I. Nicholetti et al.. 1993. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74:423–431.
   PubMed Web of Science ®Google Scholar
• Grignani, F., U. Testa, D. Rogala, P. F. Ferrucci, P. Samoggia, A. Pinto, D. Aldinucci, V. Gelmetti, M. Fagioli, M. Alcalay, J. Seeler, F. Grignani, I. Nicholetti, C. Peschle, and J. Pelicci 1996. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA biding domains. EMBO J. 15:4949–4958.
   PubMed Web of Science ®Google Scholar
• Grisolano, J. L., R. L. Wesselschmidt, P. G. Pelicci, and J. Ley 1997. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89:376–387.
   PubMed Web of Science ®Google Scholar
• Grotzinger, T., K. Jensen, H. H. Guldner, T. Sternsdorf, C. Szostecki, M. Schwab, L. Savelyeva, B. Reich, and J. Will 1996. A highly amplified mouse gene is homologous to the human interferon-responsive Sp100 gene encoding an autoantigen associated with nuclear dots. Mol. Cell. Biol. 16:1150–1156.
   PubMedGoogle Scholar
• Guidez, F., W. Huang, J. H. Tong, C. Dubois, N. Balitrand, S. Waxman, J. L. Michaux, P. Martiat, L. Degos, Z. Chen et al.. 1994. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient. Leukemia 8:312–317.
   PubMed Web of Science ®Google Scholar
• Huang, M. E., Y. C. Ye, S. R. Chen, J. R. Chai, J. X. Lu, L. Zhoa, L. J. Gu, and J. Wang 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567–572.
   PubMed Web of Science ®Google Scholar
• Kakizuka, A., W. H. Miller Jr., K. Umesono, R. P. Warrell Jr., S. R. Frankel, V. V. Murty, E. Dmitrovsky, and J. Evans 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663–674.
   PubMed Web of Science ®Google Scholar
• Kamitani, T., H. P. Nguyen, K. Kito, T. Fukuda-Kamitani, and J. Yeh 1998. Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J. Biol. Chem. 273:3117–3120.
   PubMedGoogle Scholar
• Kastner, P., A. Perez, Y. Lutz, C. Rochette-Egly, M. P. Gaub, B. Durand, M. Lanotte, R. Berger, and J. Chambon 1992. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J. 11:629–642.
   PubMed Web of Science ®Google Scholar
• Koken, M. H., F. Puvion-Dutilleul, M. C. Guillemin, A. Viron, G. Linares-Cruz, N. Stuurman, L. de Jong, C. Szostecki, F. Calvo, C. Chomienne et al.. 1994. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J. 13:1073–1083.
   PubMed Web of Science ®Google Scholar
• Koken, M. H., A. Reid, F. Quignon, M. K. Chelbi-Alix, J. M. Davies, J. H. Kabarowski, j. Zhu, S. Dong, S. Chen, Z. Chen, C. C. Tan, J. Licht, S. Waxman, H. de The, and J. Zelent 1997. Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proc. Natl. Acad. Sci. USA 94:10255–10260.
   PubMed Web of Science ®Google Scholar
• Lanotte, M., V. Martin-Thouvenin, S. Najman, P. Balerin, F. Valensi, and J. Berger 1991. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77:1080–1086.
   PubMed Web of Science ®Google Scholar
• Licht, J. D., C. Chomienne, A. Goy, A. Chen, A. A. Scott, D. R. Head, J. L. Michaux, Y. Wu, A. DeBlasio, W. H. Miller Jr. et al.. 1995. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85:1083–1094.
   PubMed Web of Science ®Google Scholar
• Lo Coco, F., G. Avvisati, D. Diverio, M. C. Petti, M. Alcalay, P. P. Pandolfi, D. Zangrilli, A. Biondi, A. Rambaldi, M. L. Moleti et al.. 1991. Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. Blood 77:1657–1659.
   PubMed Web of Science ®Google Scholar
• Mahajan, R., C. Delphin, T. Guan, L. Gerace, and J. Melchior 1997. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 88:97–107.
   PubMed Web of Science ®Google Scholar
• Mahajan, R., L. Gerace, and J. Melchior 1998. Molecular characterization of the SUMO-1 modification of RanGAP1 and its role in nuclear envelope association. J. Cell Biol. 140:259–270.
   PubMed Web of Science ®Google Scholar
• Matunis, M. J., E. Coutavas, and J. Blobel 1996. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 135:1457–1470.
   PubMed Web of Science ®Google Scholar
• Matunis, M. J., J. Wu, and J. Blobel 1998. SUMO-1 modification and its role in targeting the Ran GTPase-activating protein, RanGAP1, to the nuclear probe complex. J. Cell Biol. 140:499–509.
   PubMed Web of Science ®Google Scholar
• Muller, S., M. J. Matunis, and J. Dejean 1998. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17:61–70.
   PubMed Web of Science ®Google Scholar
• Nervi, C., F. F. Ferrara, M. Fanelli, M. R. Rippo, B. Tomassini, P. F. Ferrucci, M. Ruthardt, V. Gelmetti, C. Gambacorti-Passerini, D. Diverio, F. Grignani, P. G. Pelicci, and J. Testi 1998. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood 92:2244–2251.
   PubMed Web of Science ®Google Scholar
• Okura, T., L. Gong, T. Kamitani, T. Wada, I. Okura, C. F. Wei, H. M. Chang, and J. Yeh 1996. Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol. 157:4277–4281.
   PubMed Web of Science ®Google Scholar
• Pandolfi, P. P., F. Grignani, M. Alcalay, A. Mencarelli, A. Biondi, F. LoCoco, F. Grignani, and J. Pelicci 1991. Structure and origin of the acute promyelocytic leukemia myl/RARalpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6:1285–1292.
   PubMed Web of Science ®Google Scholar
• Perez, A., P. Kastner, S. Sethi, Y. Lutz, C. Reibel, and J. Chambon 1993. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J. 12:3171–3182.
   PubMed Web of Science ®Google Scholar
• Reid, A., A. Gould, N. Brand, M. Cook, P. Strutt, J. Li, J. Licht, S. Waxman, R. Krumlauf, and J. Zelent 1996. Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors. Am. J. Kidney Dis. 27:134–137.
   PubMedGoogle Scholar
• Ruthardt, M., A. Orleth, L. Tomassoni, E. Puccetti, D. Riganelli, M. Alcalay, R. Mannucci, I. Nicoletti, F. Grignani, M. Fagioli, and J. Pelicci 1998. The acute promyelocytic leukaemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies. Oncogene 16:1945–1953.
   PubMed Web of Science ®Google Scholar
• Ruthardt, M., U. Testa, C. Nervi, F. Ferrucci, F. Grignani, E. Puccetti, F. Grignani, C. Peschle, and J. Pelicci 1997. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor α (RARα) and PLZF-RARα fusion proteins on retinoic acid signalling. Mol. Cell. Biol. 17:4859–4869.
   PubMed Web of Science ®Google Scholar
• Schmid, I., C. H. Uittenbogaart, B. Keld, and J. Giorgi 1994. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J. Immunol. Methods 170:145–157.
   PubMed Web of Science ®Google Scholar
• Shao, W., M. Fanelli, F. F. Ferrara, R. Riccioni, A. Rosenauer, K. Davison, W. W. Lamph, S. Waxman, P. G. Pelicci, F. Lo Coco, G. Avvisati, U. Testa, C. Peschle, C. Gambacorti-Passerni, C. Nervi, W. H. Miller Jr., A. T. Look, X. Song, J. E. Bishop, W. H. Okamura, A. W. Norman, C. J. Hogan, J. S. Wiley, and J. Billington 1998. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 90:124–133.
   PubMed Web of Science ®Google Scholar
• Shen, Z., P. E. Pardington-Purtymun, J. C. Comeaux, R. K. Moyzis, and J. Chen 1996. UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins. Genomics 36:271–279.
   PubMedGoogle Scholar
• Shenk, Z. X., G. Q. Chen, J. H. Ni, X. S. Li, S. M. Xiong, Q. Y. Qiu, J. Zhu, W. Tang, G. L. Sun, K. Q. Yang, Y. Chen, L. Zhou, Z. W. Fang, Y. T. Wang, J. Ma, P. Zhang, T. D. Zhang, S. J. Chen, Z. Chen, and J. Wang 1997. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354–3360.
   PubMedGoogle Scholar
• Sternsdorf, T., H. H. Guldner, C. Szostecki, T. Grotzinger, and J. Will 1995. Two nuclear dot-associated proteins, PML and Sp100, are often coautoimmunogenic in patients with primary biliary cirrhosis. Scand. J. Immunol. 42:257–268.
   PubMed Web of Science ®Google Scholar
• Sternsdorf, T., K. Jensen, and J. Will 1997. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC-1/SUMO-1. J. Cell Biol. 139:1621–1634.
   PubMedGoogle Scholar
• Szostecki, C., H. H. Guldner, H. J. Netter, and J. Will 1990. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J. Immunol. 145:4338–4347.
   PubMed Web of Science ®Google Scholar
• Warrell, R. P. Jr.. 1993. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood 82:1949–1953 (Editorial.)
   PubMed Web of Science ®Google Scholar
• Warrell, R. P. Jr., S. R. Frankel, W. H. Miller Jr., D. A. Scheinberg, L. M. Itri, W. N. Hittelman, R. Vyas, M. Andreeff, A. Tafuri, A. Jakubowski et al.. 1991. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324:1385–1393.
   PubMed Web of Science ®Google Scholar
• Weis, K., S. Rambaud, C. Lavau, J. Jansen, T. Carvalho, M. Carmo-Fonseca, A. Lamond, and J. Dejean 1994. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76:345–356.
   PubMed Web of Science ®Google Scholar
• Yang, E., and J. Korsmeyer 1996. Molecular thanatopsis; a discourse on the BCL2 family and cell death. Blood 88:386–401.
   PubMed Web of Science ®Google Scholar
• Yoshida, H., K. Kitamura, K. Tanaka, S. Omura, T. Miyazaki, T. Hachiya, R. Ohno, and J. Naoe 1996. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res. 56:2945–2948.
   PubMed Web of Science ®Google Scholar
• Zhu, J., M. H. Koken, F. Quignon, M. K. Chelbi-Alix, L. Degos, Z. Y. Wang, Z. Chen, and J. de The 1997. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94:3978–3983.
   PubMed Web of Science ®Google Scholar